YolTech Kicks Off First-In-Class In Vivo Gene Editing Trial For TDT
Other Chinese Firms Build Presence In Field
YolTech’s early clinical stage in vivo gene editing therapy YOLT-204 may provide off-the-shelf treatment in transfusion dependent β-thalassemia without conditioning chemotherapy and HSCT.
